Oragenics Files 8-K on Feb 7, Confirms NYSE American Listing
Ticker: OGEN · Form: 8-K · Filed: Feb 7, 2024 · CIK: 1174940
Complexity: simple
Sentiment: neutral
Topics: compliance, corporate-governance, exchange-listing
TL;DR
**Oragenics filed a routine 8-K, confirming its NYSE American listing.**
AI Summary
Oragenics, Inc. filed an 8-K on February 7, 2024, to report an "Other Event" and "Financial Statements and Exhibits." This filing indicates that the company's Common Stock, with the trading symbol OGEN, is registered on the NYSE American exchange. For investors, this filing primarily serves as a routine update, confirming the company's continued compliance with SEC reporting requirements and its listing status, which is important for liquidity and visibility.
Why It Matters
This filing confirms Oragenics' ongoing compliance with SEC regulations and its listing on the NYSE American, which is crucial for maintaining investor confidence and market access.
Risk Assessment
Risk Level: low — This 8-K filing is a standard procedural update and does not contain information indicating new or increased financial or operational risks.
Analyst Insight
A smart investor would view this as a routine compliance filing, confirming Oragenics' continued listing on a major exchange, and would look for more substantive news for investment decisions.
Key Players & Entities
- Oragenics, Inc. (company) — the registrant filing the 8-K
- OGEN (company) — trading symbol for Oragenics' Common Stock
- NYSE American (company) — the exchange where Oragenics' Common Stock is registered
- February 7, 2024 (date) — date of earliest event reported and filing date
FAQ
What is the purpose of this 8-K filing by Oragenics, Inc.?
The 8-K filing by Oragenics, Inc. on February 7, 2024, is categorized under "Other Events" and "Financial Statements and Exhibits," primarily serving as a current report to update the public on events that are considered important to shareholders.
What is Oragenics, Inc.'s trading symbol and on which exchange is its stock registered?
Oragenics, Inc.'s trading symbol is OGEN, and its Common Stock is registered on the NYSE American exchange, as stated in the filing under 'Securities registered pursuant to Section 12(b) of the Act'.
When was the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is February 7, 2024, as indicated in the document.
What is the business address of Oragenics, Inc. as listed in the filing?
The business address of Oragenics, Inc. is 1990 Main Street, Suite 750, Sarasota, FL 34236, with a business phone number of 813-286-7900.
Does this 8-K filing indicate any changes to Oragenics, Inc.'s status as an emerging growth company?
The filing includes a checkbox section for 'emerging growth company' status but does not indicate a checkmark, meaning this specific 8-K does not report a change in that status or explicitly state its current status, only that it's a consideration for the filing.
Filing Stats: 435 words · 2 min read · ~1 pages · Grade level 11.2 · Accepted 2024-02-07 08:00:18
Filing Documents
- form8-k.htm (8-K) — 37KB
- ex99-1.htm (EX-99.1) — 7KB
- 0001493152-24-005201.txt ( ) — 213KB
- ogen-20240207.xsd (EX-101.SCH) — 3KB
- ogen-20240207_lab.xml (EX-101.LAB) — 33KB
- ogen-20240207_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 7 th day of February 2024. ORAGENICS, INC. (Registrant) BY: /s/Janet Huffman Janet Huffman Chief Financial Officer